IPP Bureau
Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion
By IPP Bureau - February 28, 2022
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
China’s NMPA accepts supplemental NDA for Carteyva
By IPP Bureau - February 28, 2022
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Unichem receives ANDA approval for bipolar disorder drug
By IPP Bureau - February 28, 2022
Divalproex Sodium Extended-Release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches
Europe clears blood test to predict Alzheimer’s disease
By IPP Bureau - February 28, 2022
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Cannabotech's IntegrativePain products reduce pain considerably
By IPP Bureau - February 28, 2022
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Mental wellness startup LISSUN opens centre in UP
By IPP Bureau - February 28, 2022
The company claims that this is the first time a mental wellness start-up has gone phygital in a Tier 2 city
Myonex acquires clinical trial and drug wholesale business of Hubertus in Berlin
By IPP Bureau - February 28, 2022
Clinical trial supply company strengthens its presence in the European Union
BDR Pharma launches enzalutamide in 160 mg strength
By IPP Bureau - February 28, 2022
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
First oral diabetes treatment approved in Europe for use during pregnancy
By IPP Bureau - February 28, 2022
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
Researchers develop a fast, efficient tech to remove pollutants from water
By IPP Bureau - February 28, 2022
The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes
Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr
By IPP Bureau - February 28, 2022
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Jeffrey DeAlmeida appointed Senior VP of BASF pharma solutions
By IPP Bureau - February 28, 2022
In this role, Jeffrey DeAlmeida takes responsibility for BASF’s global pharmaceutical solutions portfolio and the Nutrition & Health business in North and South America
Prenetics Partners and ACON Bio launch Covid-19 antigen kits
By IPP Bureau - February 27, 2022
Flowflex antigen test detects Covid-19, including the Omicron variant, in just 15 minutes with 98.8% accuracy
Cabinet approves Ayushman Bharat Digital Mission at an outlay of Rs 1,600 cr.
By IPP Bureau - February 27, 2022
Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked
New data reinforces efficacy of Tezspire
By IPP Bureau - February 27, 2022
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
